Supernus Pharmaceuticals, Inc. Stock price

Equities

SUPN

US8684591089

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
33.74 USD +3.88% Intraday chart for Supernus Pharmaceuticals, Inc. -3.27% +16.59%
Sales 2024 * 603M Sales 2025 * 622M Capitalization 1.85B
Net income 2024 * 14M Net income 2025 * 5M EV / Sales 2024 * 3.06 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.97 x
P/E ratio 2024 *
613 x
P/E ratio 2025 *
337 x
Employees 652
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.88%
More Fundamentals * Assessed data
Dynamic Chart
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing MT
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing MT
Transcript : Supernus Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:35 PM
Piper Sandler Cuts Price Target on Supernus Pharmaceuticals to $41 From $45, Maintains Overweight Rating MT
Transcript : Supernus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023 CI
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M MT
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Supernus Pharmaceuticals, Inc. Announces Executive Changes CI
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents MT
Supernus Pharmaceuticals Signs License Deal With Knight Therapeutics for Qelbree in Canada MT
Knight Therapeutics Brief: Entering into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada MT
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada CI
More news
1 day+3.88%
1 week-3.27%
Current month+13.60%
1 month+9.94%
3 months+13.68%
6 months+18.05%
Current year+16.59%
More quotes
1 week
32.29
Extreme 32.29
35.22
1 month
28.88
Extreme 28.875
35.44
Current year
26.27
Extreme 26.2733
35.44
1 year
21.99
Extreme 21.99
39.09
3 years
21.99
Extreme 21.99
42.09
5 years
13.12
Extreme 13.12
42.09
10 years
7.09
Extreme 7.0901
61.25
More quotes
Managers TitleAgeSince
Founder 62 05-03-29
Director of Finance/CFO 66 21-08-22
Chief Tech/Sci/R&D Officer 52 04-12-31
Members of the board TitleAgeSince
Director/Board Member 64 15-03-22
Chairman 79 05-03-29
Director/Board Member 84 10-12-31
More insiders
Date Price Change Volume
24-03-27 33.74 +3.88% 363,964
24-03-26 32.48 -0.82% 611,763
24-03-25 32.75 -5.13% 366,595
24-03-22 34.52 -1.85% 492,786
24-03-21 35.17 +0.83% 435,839

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes treatments for epilepsy, migraine, attention deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. It is also developing a range of CNS product candidates, including potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced Parkinson's disease (PD).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
33.74 USD
Average target price
40.5 USD
Spread / Average Target
+20.04%
Consensus
  1. Stock
  2. Equities
  3. Stock Supernus Pharmaceuticals, Inc. - Nasdaq